Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 25.6%

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 419,400 shares, a decrease of 25.6% from the February 28th total of 564,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is currently 0.4 days. Approximately 1.9% of the shares of the stock are short sold.

Vigil Neuroscience Price Performance

Shares of VIGL traded down $0.10 during midday trading on Thursday, hitting $1.67. The stock had a trading volume of 151,376 shares, compared to its average volume of 470,326. The stock's 50 day moving average is $2.32 and its 200 day moving average is $2.62. The firm has a market cap of $77.94 million, a PE ratio of -0.81 and a beta of 1.82. Vigil Neuroscience has a 1 year low of $1.49 and a 1 year high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.08). As a group, equities research analysts expect that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in VIGL. Cubist Systematic Strategies LLC increased its stake in Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after buying an additional 8,358 shares during the period. Jane Street Group LLC purchased a new position in shares of Vigil Neuroscience during the fourth quarter worth approximately $83,000. Barclays PLC raised its stake in shares of Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after acquiring an additional 19,436 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares during the period. Finally, Two Sigma Advisers LP increased its holdings in Vigil Neuroscience by 243.8% during the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after purchasing an additional 49,000 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on VIGL shares. HC Wainwright lowered their target price on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, March 14th. Wedbush dropped their price objective on shares of Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating for the company in a research note on Friday, March 14th. William Blair started coverage on shares of Vigil Neuroscience in a report on Wednesday, December 4th. They issued an "outperform" rating on the stock. Finally, Guggenheim reaffirmed a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Vigil Neuroscience has an average rating of "Buy" and an average target price of $16.25.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.